Press release
Oramed to Join MSCI USA Small Cap Index
NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company
About this update from Oramed Pharmaceuticals Inc.
[{"type":"text","content":"NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI USA Small Cap Index effective Tuesday, November 30th at the close of market. The MSCI USA Small Cap Index is designed to measure the performance of the small cap segment of the U.S. equity market. With 1,851 constituents, the index represents approximately 14% of the free float-adjusted market capitalization in the U.S. Key exposures of risk and return in the index include small capitalization, value, and momentum, with 14% of the index in healthcare. \n\"We welcome our inclusion in the MSCI USA Small Cap Index. Earlier this year, our stock was added to the Russell 2000®️ and Russell 3000®️ Indexes. We are pleased that inclusion of our stock in a growing number of indexes can expand our shareholder base,\" said Oramed Chief Executive Officer, Nadav Kidron. \nAbout MSCI\nMSCI is a leading provider of critical decision support tools and services for the global investment community. With over 50 years of expertise in research, data, and technology, MSCI powers better investment decisions by enabling clients to understand and analyze key drivers of risk and return and confidently build more effective portfolios. \nAbout Oramed Pharmaceuticals\nOramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901). For more information, please visit www.oramed.com.\nForward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential to expand Oramed's shareholder base or the potenti...